Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC
Status:
NOT_YET_RECRUITING
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase Ib/II combined trial of sitagliptin, XELOX chemotherapy regimen, and PD-1 monoclonal antibody in the treatment of proficient mismatch repair locally advanced colorectal cancer.
Phase:
PHASE1
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Treatments:
Capecitabine Dipeptidyl-Peptidase IV Inhibitors Oxaliplatin Sitagliptin Phosphate spartalizumab